Positively charged polymeric nanoparticle reservoirs of terbinafine hydrochloride: Preclinical implications for controlled drug delivery in the aqueous humor of rabbits

AAPS PharmSciTech

Volumn 14, Issue 2, 2013, Pages 782-793

  Tayel, Saadia Ahmed ^a   El Nabarawi, Mohamed Ahmed ^a   Tadros, Mina Ibrahim ^a   Abd Elsalam, Wessam Hamdy ^a  

^a CAIRO UNIVERSITY   (Egypt)

Author keywords

aqueous humor; chitosan; Eudragit RS100; nanoparticles; terbinafine hydrochloride

Indexed keywords

CHITOSAN; EUDRAGIT RS; MIGLYOL; NANOPARTICLE; PHOSPHATIDYLCHOLINE; POLOXAMER; TAMOXIFEN CITRATE; TERBINAFINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTERIOR EYE CHAMBER; AQUEOUS HUMOR; ARTICLE; CONTROLLED DRUG RELEASE; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG DIFFUSION; DRUG RELEASE; DRUG SOLUTION; DRUG STABILITY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; IN VITRO STUDY; IN VIVO STUDY; INFRARED SPECTROSCOPY; LACRIMAL FLUID; MALE; MEAN RESIDENCE TIME; NONHUMAN; PARTICLE SIZE; POLYMERIZATION; PRIORITY JOURNAL; RABBIT; SOLID STATE; STATIC ELECTRICITY; SURFACE CHARGE; SURFACE TENSION; TRANSMISSION ELECTRON MICROSCOPY; X RAY DIFFRACTION; ZETA POTENTIAL;

ACRYLIC RESINS; ADMINISTRATION, OPHTHALMIC; ANIMALS; ANTIFUNGAL AGENTS; AQUEOUS HUMOR; BIOLOGICAL AVAILABILITY; CHEMISTRY, PHARMACEUTICAL; CHITOSAN; CRYSTALLIZATION; CRYSTALLOGRAPHY, X-RAY; DELAYED-ACTION PREPARATIONS; DRUG CARRIERS; DRUG STABILITY; HYDROGEN-ION CONCENTRATION; LECITHINS; MALE; NANOPARTICLES; NANOTECHNOLOGY; NAPHTHALENES; OPHTHALMIC SOLUTIONS; PARTICLE SIZE; POLOXAMER; RABBITS; SOLUBILITY; SPECTROSCOPY, FOURIER TRANSFORM INFRARED; TECHNOLOGY, PHARMACEUTICAL;

EID: 84879093923     PISSN: None     EISSN: 15309932     Source Type: Journal    
DOI: 10.1208/s12249-013-9964-y     Document Type: Article

References (50)

1. Whitcher JP, Srinivasan M, Upadhyay MP. Corneal blindness: a global perspective. World Health Organization. 2001;79:214-21.
2. Bhatta RS, Chandasana H, Chhonker YS, Rathi C, Kumar D, Mitra K, et al. Mucoadhesive nanoparticles for prolonged ocular delivery of natamycin: In vitro and pharmacokinetics studies. Int J Pharm. 2012;432:105-12.
3. Tuli SS. Fungal keratitis. Clin Ophthalmol. 2011;5:275-79.
4. Shukla PK, Kumar M, Keshava GB. Mycotic keratitis: an overview of diagnosis and therapy. Mycoses. 2008;51:183-99.
5. Sweetman CS. Martindale: the complete drug reference. 37th ed. London: Pharmaceutical Press; 2011.
6. Xuguang S, Zhixin W, Zhiqun W, Shiyun L, Ran L. Ocular fungal isolates and antifungal susceptibility in Northern China. Am J Ophthalmol. 2007;143:131-33.
7. Liang QF, Jin XY, Wang XL, Sun XG. Effect of topical application of terbinafine on fungal keratitis. Chin Med J. 2009;122(16):1884-88.
8. Sun XG, Wang ZX, Wang ZQ, Deng SJ, Li R, Luo SY, et al. Pharmacokinetics of terbinafine in the rabbit ocular tissues after topical administration. Ophthalmic Res. 2007;39:81-3.
9. Pignatello R, Ricupero N, Bucolo C, Maugeri F, Maltese A, Puglisi G. Preparation and characterization of Eudragit retard nanosuspensions for the ocular delivery of cloricromene. AAPS PharmSciTech. 2006;7(1):E27.
10. Gaudana R, Ananthula HK, Parenky A, Mitra AK. Ocular Drug Delivery. AAPS J. 2010;12(3):348-60.
11. Motwani SK, Chopra S, Talegaonkar S, Kohli K, Ahmad FJ, Khar RK. Chitosan-sodium alginate nanoparticles as submicroscopic reservoirs for ocular delivery: formulation, optimization and in vitro characterization. Eur J Pharm Biopharm. 2008;68:513-25.
12. Hirano S, Seino H, Akiyama I, Nonaka I. Chitosan: a biocompatible material for oral and intravenous administration. In: Gebelein CG, Dunn RL, editors. Progress in biomedical polymers. New York: Plenum Press; 1990. p. 283-89.
13. Artursson P, Lindmark T, Davis SS, Illum L. Effect of chitosan on the permeability of monolayers of intestinal epithelial cells (Caco-2). Pharm Res. 1994;11:1358-61.
14. De Campos AM, Sanchez A, Alonso MJ. Chitosan nanoparticles: a new vehicle for the improvement of the delivery of drugs to the ocular surface. Application to cyclosporin A. Int J Pharm. 2001;224:159-68.
15. De la Fuente M, Raviña M, Paolicelli P, Sanchez A, Seijo B, Alonso MJ. Chitosan-based nanostructures: a delivery platform for ocular therapeutics. Adv Drug Del Rev. 2010;62:100-17.
16. Rowe RC, Sheskey PJ, Owen SC. Handbook of pharmaceutical excipients. 5th edn. Pharmaceutical Press and American Pharmacists Association; 2006. Electronic version.
17. Mandal B, Alexander KS, Riga AT. Sulfacetamide loaded Eudragit® RL100 nanosuspension with potential for ocular delivery. J Pharm Pharmaceut Sci. 2010;13(4):510-23.
18. Bhagav P, Upadhyay H, Chandran S. Brimonidine tartrate-Eudragit long-acting nanoparticles: formulation, optimization, in vitro and in vivo evaluation. AAPS PharmSciTech. 2011;12(4):1087-101.
19. Ibrahim HK, El-Leithy IS, Makky AA. Mucoadhesive nanoparticles as carrier systems for prolonged ocular delivery of gatifloxacin/prednisolone bitherapy. Mol Pharm. 2010;7(2):576-85.
20. Fessi H, Puisieux F, Devissaguet JP, Ammoury N, Benita S. Nanocapsule formation by interfacial polymer deposition following solvent displacement. Int J Pharm. 1989;55(1):r1-4.
21. El-Shabouri MH. Positively charged nanoparticles for improving the oral bioavailability of cyclosporin-A. Int J Pharm. 2002;249:101-08.
22. Shegokar R, Singh KK, Müller RH. Production & stability of stavudine solid lipid nanoparticles-From lab to industrial scale. Ibid. 2011;416:461-70.
23. Roland JC, Lembi CA, Morré DJ. Phosphotungstic acid-chromic acid as a selective electron-dense stain for plasma membranes of plant cells. Stain Technol. 1972;47(4):195-200.
24. Rozier A, Mazuel C, Grove J, Plazonnet B. A novel ion-activated, in-situ gelling polymer for ophthalmic vehicles. Effect on bioavailability of timolol. Int. J. Pharm. 1989;57:163-68.
25. Miyazaki S, Suzuki S, Kawasaki N, Endo K, Takahashi A, Attwood D. In situ gelling xyloglucan formulations for sustained release ocular delivery of pilocarpine hydrochloride. Int J Pharm. 2001;229(1-2):29-36.
26. Abd-Elbary A, El-laithy HM, Tadros MI. Sucrose stearate-based proniosome-derived niosomes for the nebulisable delivery of cromolyn sodium. Ibid. 2008;357:189-98.
27. Higuchi T. Mechanism of sustained action medication. J Pharm Sci. 1963;52:1145-9.
28. Piao H, Ouyang M, Xia D, Quan P, Xiao W, Song Y, et al. In vitro-in vivo study of CoQ10-loaded lipid nanoparticles in comparison with nanocrystals. Int J Pharm. 2011;419(1-2):255-9.
29. Denouël J, Keller HP, Schaub P, Delaborde C, Humbert H. Determination of terbinafine and its desmethyl metabolite in human plasma by high-performance liquid chromatography. J Chromatography B. 1995;663:353-9.
30. El-Laithy HM, Nesseem DI, El-Adly AA, Shoukry M. Moxifloxacin-Gelrite in situ ophthalmic gelling system against photodynamic therapy for treatment of bacterial corneal inflammation. Arch. Pharm. Res. 2011;34(10):1663-78.
31. Asasutjarita R, Thanasanchokpibull S, Fuongfuchat A, Veeranondha S. Optimization and evaluation of thermoresponsive diclofenac sodium ophthalmic in situ gels. Int. J. Pharm. 2011;411:128-35.
32. Bonferoni MC, Chetoni P, Giunchedi P, Rossi S, Ferrari F, Burgalassi S, et al. Carrageenan-gelatin mucoadhesive systems for ion-exchange based ophthalmic delivery: in vitro and preliminary in vivo studies. Eur. J Pharm. Biopharm 2004;57:465-72.
33. Hornig S, Heinze T, Becer CR, Schubert US. Synthetic polymeric nanoparticles by nanoprecipitation. J Mater Chem. 2009;19:3838-40.
34. Zimmer A, Kreuter J. Microspheres and nanoparticles used in ocular delivery systems. Adv Drug Del Rev. 1995;16(1):61-73.
35. Ghorab DM, Amin MM, Khowessah OM, Tadros MI. Colon-targeted celecoxib-loaded Eudragit® S100-coated poly-ε-caprolactone microparticles: preparation, characterization and in vivo evaluation in rats. Drug Del. 2011;18(7):523-35.
36. Castellanos IJ, Carrasquillo KG, de Jesus LJ, Alvarez M, Griebenow K. Encapsulation of bovine serum albumin in poly(lactide-co-glycolide) microspheres by the solid-in-oil-in-water technique. J Pharm Pharmacol. 2001;53:167-78.
37. Das S, Suresh PK. Nanosuspension: a new vehicle for the improvement of the delivery of drugs to the ocular surface. Application to amphotericin B. Nanomedicine. 2011;7(2):242-7.
38. Rodriguez M, Vila-Jato JL, Torres D. Design of new multiparticulate system for potential site specific and controlled drug delivery to the colonic region. J Control Rel. 1998;55:67-77.
39. Krishnamachari Y, Madan P, Lin S. Development of pH- and time dependent oral microparticles to optimize budesonide delivery to ileum and colon. Int J Pharm. 2007;348:238-47.
40. Atef E, Belmonte AA. Formulation and in vitro and in vivo characterization of a phenytoin self-emulsifying drug delivery system (SEDDS). Eur J Pharm Sci. 2008;35(4):257-63.
41. Pignatello R, Bucolo C, Spedalieri G, Maltese A, Puglisi G. Flurbiprofen-loaded acrylate polymer nanosuspensions for ophthalmic application. Biomaterials. 2002;23(15):3247-55.
42. Kumar N, Jain AK, Singh C, Kumar R. Development, characterization and solubility study of solid dispersion of terbinafine hydrochloride by solvent evaporation method. Asian J Pharm. 2008;2:154-8.
43. Foda NH, El-laithy HM, Tadros MI. Implantable biodegradable sponges: effect of interpolymer complex formation of chitosan with gelatin on the release behavior of tramadol hydrochloride. Drug Dev Ind Pharm. 2007 Jan;33(1):7-17.
44. Boyer RF. Transitions and relaxations in amorphous and semicrystalline organic polymers and copolymers. In: Mark HF, editor. Encyclopedia of polymer science and technology; vol II. New York: Wiley; 1977. p. 745-839.
45. Miller MH, Madu A, Samathanam G, Rush D, Madu CN, Mathisson K, et al. Fleroxacin pharmacokinetics in aqueous and vitreous humors determined by using complete concentration-time data from individual rabbits. Antimicrob Agents Chemother. 1992;36(1):32-8.
46. Mayers M, Rush D, Madu A, Motyl M, Miller MH. Pharmacokinetics of amikacin and chloramphenicol in the aqueous humor of rabbits. Antimicrob Agents Chemother. 1991;35(9):1791-8.
47. Giannavola C, Bucolo C, Maltese A, Paolino D, Vandelli MA, Puglisi G, et al. Influence of preparation conditions on acyclovir-loaded poly-d,l-lactic acid nanospheres and effect of PEG coating on ocular drug bioavailability. Pharm Res. 2003;20:584-90.
48. Mannermaa E, Vellonen KS, Urtti A. Drug transport in corneal epithelium and blood-retina barrier: emerging role of transporters in ocular pharmacokinetics. Adv Drug Deliv Rev. 2006;58:1136-63.
49. Jarvinen K, Jarvinen T, Urtti A. Ocular absorption following topical delivery. Adv Drug Deliv Rev. 1995;16:3-19.
50. Klang S, Abdulrazik M, Benita S. Influence of emulsion droplet surface charges on indomethacin ocular tissue distribution. Pharm Dev Technol. 2000;5:521-32.